<DOC>
	<DOC>NCT01970904</DOC>
	<brief_summary>This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e. viral load reduction) and safety profiles in chronic hepatitis C GT 2 and 3 treatment naïve patients.</brief_summary>
	<brief_title>Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1. Written informed consent must be obtained before any assessment is performed. 2. No previous treatment for Hepatitis C (HCV) infection (i.e. HCV treatmentnaïve) 3. Chronic hepatitis C (G2 or G3) virus infection diagnosed Exclusion criteria: 1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of that medication before enrollment. 2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes 3. Hepatitis B Surface Antigen (HBsAg) positive 4. Human immunodeficiency virus (HIV) positive.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>DEB025</keyword>
	<keyword>Alisporivir</keyword>
	<keyword>ribavirin therapy</keyword>
	<keyword>genotype 2/3 treatment naive patients</keyword>
</DOC>